ATLAS-A/B: A Phase 3 study to evaluate the efficacy and safety of fitusiran in patients with hemophilia A or B, without inhibitory antibodies to factor VIII or IX

Genzyme Corporation0 sites120 target enrollmentAugust 30, 2017

Overview

No summary available.

Registry

who.int

Start Date

August 30, 2017

End Date

July 14, 2021

Last Updated

4 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

Male

Sponsor

•Males \=12 years of age.
•Severe hemophilia A or B without inhibitors evidenced by:
•a. A central laboratory measurement or documented medical record evidence of FVIII \<1% or FIX level \=2% at Screening.
•b. On\-demand use of factor concentrate to manage bleeding episodes for at least the last 6 months prior to Screening, and meet each of the
•following criterion:
•Nijmegen modified Bethesda assay inhibitor titer of \<0\.6 BU/mL at Screening
•No use of BPAs to treat bleeding episodes for at least the last 6 months prior to Screening
•No history of immune tolerance induction therapy within the last 3 years prior to Screening
•A minimum of 6 bleeding episodes requiring factor concentrate treatment within the last 6 months prior to Screening.
•Willing and able to comply with the study requirements and to provide written informed consent and assent in the case of patients under the age of legal consent, per local and national requirements.

•Patients with known co\-existing bleeding disorders other than hemophilia A or B
•Patients with clinically significant liver disease
•Patients known to be HIV positive and have a CD4 count \<200 cells/µL
•Patients with a history of arterial or venous thromboembolism
•Estimated glomerular filtration rate \=45 mL/min/1\.73m2 (using the Modification of Diet in Renal Disease \[MDRD] formula)
•Patients with a co\-existing thrombophilic disorder
•Patients with a history of multiple drug allergies or history of allergic reaction to an oligonucleotide or GalNAc
•Patients with a history of intolerance to SC injection(s)
•Patients with an anticipated or planned need for surgery during the study
•Any other conditions or comorbidities that would make the patient unsuitable for enrollment or could interfere with participation in or completion of the study, per Investigator judgement